Meningococcal polysaccharide conjugate vaccine
AssigneeNational Research Council of Canada
InventorsHarold J. Jennings, Francis Michon
Life of this patent
Estimating the term…
Abstract
Neisseria meningitidis group B polysaccharide (GBMP) modified by having sialic acid residue N-acetyl groups replaced by N-acyl groups exhibits enhanced immuno response thereto. In addition, induction of antibodies which cross-react with unmodified group B meningococcal and E. coli K1 capsular polysaccharide and other tissue cells having a common epitope is minimized. Conjugation of the modified polysaccharides with a physiologically acceptable protein such as tetanus toxoid induces the production of specific protective antibodies with negligible levels of GBMP-cross reactive antibodies, to thereby afford protection against infections caused by group B meningococci and E. coli K1.
Claims9
A gamma globulin fraction comprising antibodies directed against group B N. meningitidis or E. coli K1, said gamma globulin fraction being produced by immunizing a mammal with an antigenic conjugate comprising a modified group B polysaccharide of Neisseria meningitidis or E. coli K1 having sialic acid N-acetyl residue groups replaced by a N--C4-C.sub.8 -acyl group conjugated to an immunologically-suitable protein, wherein the the N-acetyl groups are replaced with the N--C.sub.4 -C.sub.8 acyl groups to an extent that when said modified group B polysaccharide is conjugated to said protein the amount of substitution of acyl for acetyl groups is sufficient to reduce the inducement of antibodies which bind native GBMP, compared to the binding of native GBMP to antibodies induced by a N-pr-GBMP-protein conjugate--has been inserted.
The gamma globulin fraction according to 3, wherein the C.sub.4 -C.sub.8 acyl group of the conjugate used to immunize the mammal is n-butanoyl.
Dependencies are inferred from the claim text.